Drug Trial Radar · NCT02879578
Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome
Last checked: Nov 20, 2026Latest source record: Apr 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
155
Actual
Start
Jul 25, 2016
Primary completion
Nov 1, 2017
Study completion Nov 1, 2017
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Aug 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 64 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).
Conditions
- Tourette Syndrome
Interventions
ValbenazineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline through Week 28
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Sun City, Arizona
Site not named
San Diego, California
Site not named
Loxahatchee Groves, Florida
Site not named
St. Petersburg, Florida
Site not named
Tampa, Florida
Site not named
Naperville, Illinois
Site not named
Lincoln, Nebraska
Site not named
Summit, New Jersey
Site not named
New York, New York
Site not named
Norristown, Pennsylvania
Site not named
Nashville, Tennessee
Site not named
Fort Worth, Texas
Site not named
Spokane, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.